Introduction: We performed a meta-analysis to assess the role of immune checkpoint inhibitors as second-line therapy in EGFR-mutant advanced NSCLC. VSports手机版.

Methods: Randomized trials comparing immune checkpoint inhibitors against chemotherapy were identified. We retrieved the hazard ratio (HR) and 95% confidence interval (CI) for overall survival (OS) of the intention-to-treat population and EGFR mutation-defined subgroups. We used the fixed-effects inverse variance-weighted method to pool estimates of treatment efficacy. Statistical tests were two sided. V体育安卓版.

Results: In the three included studies that compared immune checkpoint inhibitors (nivolumab [n = 292], pembrolizumab [n = 691], and atezolizumab [n =144]) against docetaxel (n = 776), immune checkpoint inhibitors significantly prolonged OS over that with docetaxel overall (n = 1903, HR = 0. 68, 95% CI: 0 V体育ios版. 61-0. 77, p < 0. 0001) and in the EGFR wild-type subgroup (n = 1362, HR = 0. 66, 95% CI: 0. 58-0. 76, p < 0. 0001) but not in the EGFR-mutant subgroup (n = 186, HR = 1. 05, 95% CI: 0. 70-1. 55, p < 0. 81; treatment-mutation interaction p = 0. 03). .

Conclusion: In EGFR-mutant advanced NSCLC, immune checkpoint inhibitors do not improve OS over that with docetaxel VSports最新版本. Mechanisms of acquired resistance to first-line tyrosine kinase inhibitor therapy should be elucidated to guide selection of second-line treatment for these patients. .